RxDoctor Payments Data

Daniel Raines, MD

Gastroenterology · Kenner, LANPI 1316081367

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Fujifilm Healthcare Americas Corporation at 48.3% of the total. Reporting peaked in 2023 at $11,810 and has fallen 92.5% since, to $886 in 2025. Among gastroenterology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,776in general payments, 2019–2025

Across 138 payments — averaging $266.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fujifilm Healthcare Americas Corporation$18K
  • Medtronic$10K
  • Covidien LP$6K
  • AbbVie$481
  • Pfizer$433
  • Gilead$339
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$20,85057%
  • Speaking & faculty fees$8,10022%
  • Travel & lodging$4,95013%
  • Food & beverage$2,8768%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,776 in reported general payments places this provider in the 90th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana

Medicare billing

Part B allowed, 2024
$52,695
Medicare patients
161
Services billed
352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin18$59,118
CreonLipase/Protease/Amylase17$55,452
LinzessLinaclotide63$48,722
Erythromycin Ethylsuccinate15$18,458
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates111$7,164
Alosetron Hcl11$4,879
Sucralfate19$2,422
Misoprostol28$2,407
Esomeprazole Magnesium24$950
Dicyclomine Hcl38$613
Omeprazole20$374
Pantoprazole Sodium63$333
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl17$283
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl14$277
Amitriptyline Hcl18$254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$481$104,17480 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$254$59,11818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 254 gastroenterology providers in Louisiana.

Other gastroenterology in Kenner

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →